Table I.
Risk stratification (the TCCSG L99-1502 study).
| A, B-lineage ALL | |||
|---|---|---|---|
|
| |||
| Years | |||
|
|
|||
| Initial risk | 1–6 | 7–9 | ≥10 |
| Initial leukocyte count, ×109/l | |||
| <20 | SR | IR | IR |
| 20–49 | IR | IR | IR |
| 50–99 | IR | IR | HR |
| ≥100 | HR | HR | HR |
|
| |||
| B, B-lineage ALL | |||
|
| |||
| Days | |||
|
|
|||
| Day 8 risk | 1 SR | 1 IR | 1 HR |
|
| |||
| Day 8 PB blasts/μl | |||
| 0 | SR | IR | IR |
| 1–999 | SR | IR | HR |
| ≥1,000 | IR | HR | Allo-SCT |
|
| |||
| C, T-lineage ALL | |||
|
| |||
| Day 8 risk | All patients | ||
|
| |||
| Day 8 PB blasts/μl | |||
| 0 | IR | ||
| 1–999 | HR | ||
| ≥1,000 | Allo-SCT | ||
PB, peripheral blood; SR, standard-risk; IR, intermediate-risk; HR, high-risk; Allo-SCT, allogeneic stem cell transplantation; ALL; acute lymphoblastic leukemia.